ProMIS Neurosciences Announces Second Quarter 2026 Financial Results and Provides Corporate Highlights

Announced positive blinded six-month interim safety and biomarker results from PRECISE-AD, the Company's Phase 1b trial of PMN310 in patients with early Alzheimer's disease (AD), including zero cases...